TNSN08506A1 - Substituted carboxamides - Google Patents

Substituted carboxamides

Info

Publication number
TNSN08506A1
TNSN08506A1 TNP2008000506A TNSN08506A TNSN08506A1 TN SN08506 A1 TNSN08506 A1 TN SN08506A1 TN P2008000506 A TNP2008000506 A TN P2008000506A TN SN08506 A TNSN08506 A TN SN08506A TN SN08506 A1 TNSN08506 A1 TN SN08506A1
Authority
TN
Tunisia
Prior art keywords
substituted carboxamides
substituted
carboxamides
carboxarnide
compound
Prior art date
Application number
TNP2008000506A
Other languages
English (en)
Inventor
Ryan Thomas Backer
Matthew Joseph Fisher
Steven Lee Kuklish
Sean Patrick Hollinshead
Edward C R Smith
Kumiko Takeuchi
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of TNSN08506A1 publication Critical patent/TNSN08506A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D275/00Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TNP2008000506A 2006-06-08 2008-12-05 Substituted carboxamides TNSN08506A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81183906P 2006-06-08 2006-06-08
PCT/US2007/070572 WO2008103185A2 (en) 2006-06-08 2007-06-07 Substituted carboxamides as group i metabotropic receptor antagonists

Publications (1)

Publication Number Publication Date
TNSN08506A1 true TNSN08506A1 (en) 2010-04-14

Family

ID=39673278

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2008000506A TNSN08506A1 (en) 2006-06-08 2008-12-05 Substituted carboxamides

Country Status (30)

Country Link
US (1) US7960419B2 (enExample)
EP (1) EP2076502B1 (enExample)
JP (1) JP5108878B2 (enExample)
KR (1) KR101051559B1 (enExample)
CN (1) CN101466691B (enExample)
AT (1) ATE509921T1 (enExample)
AU (1) AU2007347428B2 (enExample)
BR (1) BRPI0712862A2 (enExample)
CA (1) CA2652074C (enExample)
CR (1) CR10410A (enExample)
CY (1) CY1111588T1 (enExample)
DK (1) DK2076502T3 (enExample)
EA (1) EA014233B1 (enExample)
EC (1) ECSP088939A (enExample)
ES (1) ES2362949T3 (enExample)
HR (1) HRP20110436T1 (enExample)
IL (1) IL195632A (enExample)
MA (1) MA30620B1 (enExample)
MX (1) MX2008015485A (enExample)
MY (1) MY148084A (enExample)
NO (1) NO341474B1 (enExample)
NZ (1) NZ573352A (enExample)
PL (1) PL2076502T3 (enExample)
PT (1) PT2076502E (enExample)
RS (1) RS51818B (enExample)
SI (1) SI2076502T1 (enExample)
TN (1) TNSN08506A1 (enExample)
UA (1) UA95480C2 (enExample)
WO (1) WO2008103185A2 (enExample)
ZA (1) ZA200809111B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0804685D0 (en) 2008-03-13 2008-04-16 Univ Edinburgh Therapeutic compounds and their use
MX2010010781A (es) 2008-04-04 2010-12-14 Lilly Co Eli 3-indazolil-4-piridilisotiazoles.
EP2443113A1 (en) * 2009-06-15 2012-04-25 The University Of Edinburgh Amido-isothiazole compounds and their use as inhibitors of 11beta-hsd1 for the treatment of metabolic syndrome and related disorders
JP5779181B2 (ja) 2009-09-16 2015-09-16 ザ ユニバーシティ オブ エディンバラ (4−フェニル−ピペリジン−1−イル)−[5−(1h−ピラゾール−4−イル)−チオフェン−3−イル]−メタノン化合物及びそれらの使用
EP2563780B1 (en) 2010-04-29 2015-05-06 The University Of Edinburgh 3,3-disubstituted-(8-aza-bicyclo[3.2.1]oct-8-yl)-[5-(1h-pyrazol-4-yl)-thiophen-3-yl]-methanones as inhibitors of 11(beta)-hsd1
DK2921489T3 (en) 2012-11-13 2017-10-16 Nissan Chemical Ind Ltd 2-pyridone-RELATED
AU2017329677A1 (en) 2016-09-23 2019-04-18 Bayer Aktiengesellschaft N 3 -cyclically substituted thienouraciles and use thereof
CN117567266B (zh) * 2023-11-07 2024-06-14 康龙化成手性医药技术(宁波)有限公司 一种制备2-甲基环丙羧酸的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL72091A0 (en) 1983-06-20 1984-10-31 Lilly Co Eli N'-substituted(3-aryl 5-isothiazolyl)urea derivatives
DE4328425A1 (de) 1993-08-24 1995-03-02 Basf Ag Acylamino-substituierte Isoxazol- bzw. Isothiazolderivate, Verfahren zu deren Herstellung und ihre Verwendung
DK124393D0 (da) 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds
DE19542372A1 (de) * 1995-11-14 1997-05-15 Bayer Ag Acylierte 5-Aminoisothiazole
UA60365C2 (uk) * 1998-06-04 2003-10-15 Пфайзер Продактс Інк. Похідні ізотіазолу, спосіб їх одержання, фармацевтична композиція та спосіб лікування гіперпроліферативного захворювання у ссавця
JP3411262B2 (ja) * 1999-08-20 2003-05-26 萬有製薬株式会社 新規スピロ化合物
JP2005501073A (ja) * 2001-08-06 2005-01-13 フアルマシア・イタリア・エツセ・ピー・アー キナーゼ阻害薬活性を有するアミノイソオキサゾール誘導体
EP1667983A4 (en) * 2003-09-23 2010-07-21 Merck Sharp & Dohme PYRAZOL MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS
WO2005113534A2 (en) * 2004-05-12 2005-12-01 Schering Corporation Cxcr1 and cxcr2 chemokine antagonists
BRPI0515571A (pt) * 2004-09-23 2008-07-29 Pfizer Prod Inc agonistas de receptor de trombopoetina

Also Published As

Publication number Publication date
EP2076502A2 (en) 2009-07-08
JP2009539874A (ja) 2009-11-19
MY148084A (en) 2013-02-28
CA2652074A1 (en) 2008-08-28
MX2008015485A (es) 2009-03-06
EA014233B1 (ru) 2010-10-29
PT2076502E (pt) 2011-06-07
RS51818B (sr) 2011-12-31
SI2076502T1 (sl) 2011-09-30
DK2076502T3 (da) 2011-07-25
KR101051559B1 (ko) 2011-07-22
ECSP088939A (es) 2009-01-30
IL195632A0 (en) 2009-09-01
HRP20110436T1 (hr) 2011-08-31
CR10410A (es) 2008-11-28
US20090182025A1 (en) 2009-07-16
EA200870516A1 (ru) 2009-06-30
NO341474B1 (no) 2017-11-27
AU2007347428A1 (en) 2008-08-28
CN101466691A (zh) 2009-06-24
EP2076502B1 (en) 2011-05-18
JP5108878B2 (ja) 2012-12-26
ES2362949T3 (es) 2011-07-15
WO2008103185A2 (en) 2008-08-28
PL2076502T3 (pl) 2011-09-30
WO2008103185A3 (en) 2008-10-30
ATE509921T1 (de) 2011-06-15
ZA200809111B (en) 2009-12-30
CY1111588T1 (el) 2015-10-07
NO20085028L (no) 2008-12-02
IL195632A (en) 2013-11-28
AU2007347428B2 (en) 2012-02-09
CN101466691B (zh) 2011-07-27
HK1131984A1 (en) 2010-02-12
CA2652074C (en) 2013-08-06
BRPI0712862A2 (pt) 2012-12-18
KR20090008460A (ko) 2009-01-21
US7960419B2 (en) 2011-06-14
UA95480C2 (uk) 2011-08-10
NZ573352A (en) 2011-10-28
MA30620B1 (fr) 2009-08-03

Similar Documents

Publication Publication Date Title
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
TW201000473A (en) Benzene or thiophene derivative and use thereof as VAP-1 inhibitor
TNSN08506A1 (en) Substituted carboxamides
TW200806299A (en) Treatment of pain
NZ601483A (en) Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
MX2011012122A (es) Derivados de tiofeno.
TW200806300A (en) New therapeutic combinations for the treatment of depression
UA93709C2 (ru) 12-имидазолил-1-додеканол и его применение b изготовлении фармацевтических композиций
MX2010009395A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y procesos para preparacion de los mismos.
IL193252A0 (en) N-hydroxyacrylamide compounds
TNSN07419A1 (en) Methods for treating drug resistant cancer
MY143568A (en) 11b-hsd1 inhibitors for the treatment of diabetes
MX2010009756A (es) Agonistas de receptores muscarinicos, composiciones, metodos de tratamiento de los mismos, y proceso para preparacion de los mismos.
WO2010121675A3 (en) Thiazolyl-benzimidazoles
MX2009005798A (es) Recuperacion de apoplejia.
MX2009006325A (es) Compuestos de heteroaril-heteroarilo como inhibidores de cdk para el tratamiento de cancer, inflamacion e infecciones virales.
TW200639159A (en) Treatment of pain
WO2007133796A3 (en) Methods and compositions for treatment of sleep apnea comprising administration of an endothelin antagonist
TW200800993A (en) Organic compounds
DE602007007934D1 (en) Imidazoazephinonverbindungen
WO2007144889A3 (en) Treatment of neurofibromatosis
IL197769A (en) The history of morphine, medicinal preparations containing them and their use in the preparation of pain medication
MX2008011017A (es) Compuestos de receptor sigma.
AU2016219620A1 (en) Compositions and methods useful for treatment of respiratory illness